|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023467,
umls-concept:C0026882,
umls-concept:C0026986,
umls-concept:C0030705,
umls-concept:C0287186,
umls-concept:C0442027,
umls-concept:C0526371,
umls-concept:C0597357,
umls-concept:C0915830,
umls-concept:C1171350,
umls-concept:C1333568,
umls-concept:C1706096
|
|
pubmed:issue |
28
|
|
pubmed:dateCreated |
2010-9-30
|
|
pubmed:abstractText |
Mutations leading to constitutive activation of the FMS-like tyrosine kinase 3 receptor (FLT3) occur in blasts of 30% of patients with acute myeloid leukemia (AML). Midostaurin (PKC412; N-benzoylstaurosporin) is a multitargeted tyrosine kinase inhibitor, with demonstrated activity in patients with AML/myelodysplastic syndrome (MDS) with FLT3 mutations.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:CarloLanzaL,
pubmed-author:DeangeloDaniel JDJ,
pubmed-author:DutreixCatherineC,
pubmed-author:EhningerGerhardG,
pubmed-author:EsteyElihuE,
pubmed-author:FeldmanEric JEJ,
pubmed-author:FischerThomasT,
pubmed-author:FoxEdwardE,
pubmed-author:GalinskyIleneI,
pubmed-author:GilesFrancis JFJ,
pubmed-author:GillilandD GaryDG,
pubmed-author:Huntsman-LabedAliceA,
pubmed-author:KlimekVirginia MVM,
pubmed-author:NimerStephen DSD,
pubmed-author:SchillerGary JGJ,
pubmed-author:StoneRichard MRM,
pubmed-author:VirkusJodiJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4339-45
|
|
pubmed:meshHeading |
pubmed-meshheading:20733134-Administration, Oral,
pubmed-meshheading:20733134-Aged,
pubmed-meshheading:20733134-Antineoplastic Agents,
pubmed-meshheading:20733134-Female,
pubmed-meshheading:20733134-Humans,
pubmed-meshheading:20733134-Leukemia, Myeloid, Acute,
pubmed-meshheading:20733134-Male,
pubmed-meshheading:20733134-Mutation,
pubmed-meshheading:20733134-Myelodysplastic Syndromes,
pubmed-meshheading:20733134-Receptor Protein-Tyrosine Kinases,
pubmed-meshheading:20733134-Staurosporine,
pubmed-meshheading:20733134-Treatment Outcome,
pubmed-meshheading:20733134-fms-Like Tyrosine Kinase 3
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
|
|
pubmed:affiliation |
Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
